Drugs / Rhenium-188-HEDP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03458559 | May 2018 → May 2022 | metastatic prostate carcinoma | Amsterdam UMC, location VUmc | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rhenium-188-HEDP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03458559 ↗ |
| Modality | Other / unclassified | “rhenium-188-HEDP (a beta-emitting radiopharmaceutical)” NCT03458559 ↗ |
| Route | Intravenous | “Intravenously 40 MBq/kg every 8 weeks” NCT03458559 ↗ |